Judgment of the General Court of 26 January 2017 — Opko Ireland Global Holdings v EUIPO — Teva Pharmaceutical Industries (ALPHAREN)
(Case T-88/16) 1
(EU trade mark — Opposition proceedings — Application for EU word mark ALPHAREN — Earlier national word marks ALPHA D3 — Relative ground for refusal — Likelihood of confusion — Article 8(1)(b) of Regulation (EC) No 207/2009 — Consideration of new evidence by the Board of Appeal following a judgment annulling a decision — Article 76(2) of Regulation No 207/2009)
Language of the case: English
Parties
Applicant: Opko Ireland Global Holdings Ltd (Dublin, Ireland) (represented by: S. Malynicz QC, A. Smith and D. Meale, Solicitors)
Defendant: European Union Intellectual Property Office (represented by: A. Folliard-Monguiral, acting as Agent)
Other party to the proceedings before the Board of Appeal of EUIPO: Teva Pharmaceutical Industries Ltd (Jerusalem, Israel)
Re:
Action brought against the decision of the Fifth Board of Appeal of EUIPO of 16 December 2015 (Case R 2387/2014-5), relating to opposition proceedings between Teva Pharmaceutical Industries and Opko Ireland Global Holdings.
Operative part of the judgment
The Court:
Dismisses the action;
2.    Orders Opko Ireland Global Holdings Ltd to pay the costs.
____________
1     OJ C 136, 18.4.2016.